Algethami A, Alahmadi SS, AlQahtani A, Balghith M. Survival outcomes of elderly patients undergoing transcatheter aortic valve implantation after 3 years of follow-up. World J Cardiol 2026; 18(2): 114983 [DOI: 10.4330/wjc.v18.i2.114983]
Corresponding Author of This Article
Abdulrahman AlQahtani, MD, Department of Cardiology, Taif Health Cluster, Government Complex, City Center, At Ta'if 26311, Makkah al Mukarramah, Saudi Arabia. a.s.alqahtni@gmail.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 26, 2026 (publication date) through Feb 9, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Algethami A, Alahmadi SS, AlQahtani A, Balghith M. Survival outcomes of elderly patients undergoing transcatheter aortic valve implantation after 3 years of follow-up. World J Cardiol 2026; 18(2): 114983 [DOI: 10.4330/wjc.v18.i2.114983]
World J Cardiol. Feb 26, 2026; 18(2): 114983 Published online Feb 26, 2026. doi: 10.4330/wjc.v18.i2.114983
Survival outcomes of elderly patients undergoing transcatheter aortic valve implantation after 3 years of follow-up
Abdulaziz Algethami, Salman Salem Alahmadi, Abdulrahman AlQahtani, Mohammed Balghith
Abdulaziz Algethami, Mohammed Balghith, Adult Cardiology, King Abdulaziz Cardiac Center, King Abdulaziz Medical City for National Guard, Riyadh 14611, Ar Riyadh, Saudi Arabia
Abdulaziz Algethami, Salman Salem Alahmadi, Mohammed Balghith, Collage of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh 14611, Ar Riyadh, Saudi Arabia
Abdulaziz Algethami, Mohammed Balghith, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University, Riyadh 14611, Ar Riyadh, Saudi Arabia
Salman Salem Alahmadi, Abdulrahman AlQahtani, King Abdulaziz Cardiac Center, King Abdulaziz Medical City for National Guard, Ministry of National Guard Health Affairs, Riyadh 14611, Ar Riyadh, Saudi Arabia
Abdulrahman AlQahtani, Department of Cardiology, Taif Health Cluster, At Ta'if 26311, Makkah al Mukarramah, Saudi Arabia
Author contributions: Algethami A and Balghith M designed the report; Alahmadi SS collected the patient’s clinical data; AlQahtani A analyzed the data and wrote the paper; all authors read and approved the final manuscript.
Institutional review board statement: This study was approved by the Institutional Review Board of King Abdullah International Medical Research Center.
Informed consent statement: Due to the retrospective design, the requirement for informed consent was waived. All data were anonymized prior to analysis, and patient privacy and confidentiality were strictly maintained in accordance with institutional and international ethical standards (Declaration of Helsinki).
Conflict-of-interest statement: The authors declare no conflicts of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement:
The datasets generated and/or analyzed during the current study are not publicly available due to institutional restrictions and patient privacy concerns but are available from the corresponding author on reasonable request and with permission from King Abdullah International Medical Research Center.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Abdulrahman AlQahtani, MD, Department of Cardiology, Taif Health Cluster, Government Complex, City Center, At Ta'if 26311, Makkah al Mukarramah, Saudi Arabia. a.s.alqahtni@gmail.com
Received: October 11, 2025 Revised: October 25, 2025 Accepted: December 12, 2025 Published online: February 26, 2026 Processing time: 128 Days and 17.4 Hours
Abstract
BACKGROUND
Severe aortic stenosis is typically treated with transcatheter aortic valve implantation (TAVI) in elderly patients with contraindications for surgery or elderly patients who have a high risk for surgical aortic valve replacement. Currently, there is a paucity of data on the survival outcomes for patients older than 85 years who underwent TAVI.
AIM
To determine survival and predictors of mortality in patients older than 85 years who underwent TAVI.
METHODS
A retrospective cohort study was conducted on 64 patients ≥ 85 years of age who underwent TAVI between 2010 and 2023 at the King Abdulaziz Cardiac Center in Riyadh, Saudi Arabia. Baseline demographics, echocardiographic parameters, procedural outcomes, and mortality data were collected and analyzed at the 1-year and 3-year follow-up appointments.
RESULTS
The mean patient age was 88.3 ± 3.6 years, and 81.3% of the patients were male. The most common comorbidities were hypertension (79.7%), diabetes (60.9%), and coronary artery disease (53.1%). The mean left ventricular ejection fraction was 51.1% with a mean transvalvular gradient of 45.1 mmHg. The 1-year and 3-year survival rates were 82% and 63%, respectively. The mean survival duration was 56.3 months. Multivariate analysis identified body mass index ≥ 30 as significant predictor of early mortality (odds ratio: 3.13, 95% confidence interval: 1.01-4.75).
CONCLUSION
Favorable survival outcomes were observed in patients 85 years or older who underwent TAVI. The mortality risk increased in patients with obesity.
Core Tip: Transcatheter aortic valve implantation (TAVI) demonstrated favorable mid-term survival in our cohort of elderly patients aged 85 years or older. The 1-year and 3-year survival rates were 82% and 63%, respectively. Mortality risk increased in patients with obesity. Advanced age alone should not be a contraindication for TAVI.
